Skip to content
Basket0
Basket

Your basket is empty.

Your basket is empty.

View basket
☰

Novonorm

Novonorm
In stock
0,5mg · 1mg · 2mg
from 20,23 £
Strength
Pack size — the bigger the pack, the cheaper the tablet
24,28 £20,23 £
0,67 £ per tablet

In brief

  • In our pharmacy, you can buy NovoNorm without a prescription, with delivery in 9–21 days throughout the United Kingdom. Discreet and anonymous packaging.
  • NovoNorm (repaglinide) is used to treat type 2 diabetes mellitus; it is a rapid‑acting insulin secretagogue (meglitinide) that stimulates pancreatic beta‑cells to release insulin by closing ATP‑dependent potassium channels.
  • The usual dose is 0.5 mg orally with each main meal (1 mg when transferring from another oral antidiabetic), adjusted every 1–2 weeks as needed up to a maximum single dose of 4 mg and total daily maximum of 16 mg.
  • The form of administration is oral tablets (available in 0.5 mg, 1 mg and 2 mg strengths), taken just before meals.
  • The effect of the medication begins within about 15–30 minutes after dosing.
  • The duration of action is short‑acting, approximately 4–6 hours per dose.
  • Avoid alcohol; it can increase the risk of hypoglycaemia and adversely affect blood glucose control.
  • The most common side effect is hypoglycaemia; other common effects include abdominal pain and diarrhoea.
  • Would you like to try NovoNorm without a prescription?

Basic NovoNorm information

  • INN (international nonproprietary name): Repaglinide
  • Brand names available in the United Kingdom: NovoNorm; generic repaglinide.
  • ATC code: A10BX02
  • Forms and dosages: Tablets 0.5 mg, 1 mg, 2 mg.
  • Manufacturers in the United Kingdom: Novo Nordisk (NovoNorm); generic manufacturers.
  • Registration status in the United Kingdom: Prescription-only medicine (POM).
  • OTC / Rx classification: Prescription-only medicine (POM).

Critical warnings and restrictions

High-risk groups (elderly, pregnancy, chronic illness)

  • Absolute contraindications: Type 1 diabetes and diabetic ketoacidosis.
  • Drug contraindication: Concomitant gemfibrozil is contraindicated because of a risk of severe hypoglycaemia.
  • Elderly: Increased risk of hypoglycaemia; start low and monitor closely.
  • Hepatic impairment: Contraindicated in severe hepatic impairment; use caution and start at the lowest dose in mild-to-moderate disease.
  • Renal impairment: Start at the lowest dose (0.5 mg) and titrate cautiously with monitoring.
  • Pregnancy and breastfeeding: Avoid unless a diabetes specialist advises otherwise; discuss with a diabetes specialist midwife or consultant.
  • Pharmacovigilance: Report suspected adverse reactions via the MHRA Yellow Card.

Practical patient checklist:

  • Carry a fast-acting glucose source at all times (glucose tablets or sugary snack).
  • Wear medical identification stating you take an insulin secretagogue.
  • Keep an emergency contact and hypoglycaemia action plan accessible.
  • Review all medicines with your pharmacist, especially lipid-lowering or interacting drugs.
  • Report suspected side effects through the Yellow Card system.

Interaction with activities (driving, workplace safety under UK law)

Hypoglycaemia from repaglinide can impair concentration, reaction times and co-ordination.

Driving and machine operation should only occur if you know you do not get hypoglycaemia and your blood glucose is in a safe range before you start.

The DVLA requires drivers to inform them if they experience recurrent severe hypoglycaemia or loss of hypoglycaemia awareness.

Employers must be informed if a safety-critical role is affected so that a workplace risk assessment can be completed.

Q&A — “Can I drive after taking it in the UK?”

Q: Can I drive after taking repaglinide?

A: Only if you know you do not get hypoglycaemia and your blood glucose is safe before driving.

A: If you experience hypoglycaemia, you must not drive and must follow DVLA and NHS guidance.

A: Report severe episodes to your clinician and ensure they are recorded in your medical records.

Usage basics

INN, brand names available in the UK

  • NovoNorm — brand of repaglinide tablets.
  • Repaglinide generics — available on prescription.
  • Tablet strengths: 0.5 mg, 1 mg, 2 mg.
ATC code
A10BX02
Classification
Meglitinide (glinide); rapid-acting prandial insulin secretagogue for type 2 diabetes management.

Legal classification (POM, P, GSL)

Repaglinide is a prescription-only medicine (POM) in the UK.

In the UK it must be prescribed by an authorised prescriber under NHS or private prescription rules.

Electronic prescriptions (EPS) are widely used and pharmacists must ensure safe supply and counsel on hypoglycaemia risk and interactions.

Dosing guide

Standard regimens (NHS guidelines)

Initial adult dosing is usually 0.5 mg orally with each main meal.

Patients transferring from another oral antidiabetic usually start at 1 mg with each main meal.

Dose may be adjusted at intervals of 1–2 weeks up to a single dose of 4 mg and a total daily maximum of 16 mg.

Situation Initial dose per main meal Titration plan
Starting treatment 0.5 mg Adjust every 1–2 weeks to achieve prandial control; max single dose 4 mg
Transferring from another oral antidiabetic 1 mg Adjust every 1–2 weeks to effect; total daily max 16 mg

Timing around meals:

  • Take repaglinide 0–30 minutes before each main meal to blunt postprandial glucose spikes.
  • If a meal is skipped, skip the dose for that meal; do not double the next dose.

Adjustments for comorbidities

Start at the lowest dose in elderly patients and in those with renal impairment, with careful monitoring for hypoglycaemia.

Avoid use in severe hepatic impairment and use caution with mild-to-moderate liver dysfunction, starting at the lowest dose and monitoring clinically.

Monitor blood glucose more frequently when combined with other insulin secretagogues or insulin because of additive hypoglycaemia risk.

Q&A — “What if I miss a dose?”

Q: What if I miss a dose of repaglinide?

A: If you miss a dose because you skipped the meal, skip that dose and take the next dose with the next main meal.

A: Do not double up doses to make up for a missed one.

A: If unsure, contact your pharmacist or prescriber for personalised advice.

Interaction chart

Food and drinks (alcohol, tea/coffee, diet habits)

Repaglinide is intended as a mealtime medicine to reduce postprandial glucose peaks, so timing with food is crucial.

Alcohol increases the risk of hypoglycaemia and may blunt warning symptoms and recovery.

Caffeine has no major direct pharmacological interaction but can affect appetite and meal timing, which in turn affects dosing schedules.

Substance Effect Patient advice
Alcohol Increases hypoglycaemia risk; blunts warning signs Avoid binge drinking; discuss usual drinking patterns with clinician
Caffeine (tea/coffee) No major direct interaction Mind meal timing; take repaglinide 0–30 minutes before meals
Irregular meals/shift work Higher hypoglycaemia risk if doses are taken without food Adjust dosing or consider alternative agents if meals are unpredictable

Common drug conflicts

  • Gemfibrozil — contraindicated due to risk of severe hypoglycaemia when given with repaglinide.
  • Concurrent insulin or sulfonylureas — additive hypoglycaemia risk; monitor closely.
  • CYP3A4 and CYP2C8 modulators — strong inhibitors or inducers may alter repaglinide exposure; consult BNF/MHRA.
  • Lipid-lowering agents, antifungals, macrolides, protease inhibitors — review these for interactions and report concerns via Yellow Card.
Interaction Severity Action
Gemfibrozil Severe Contraindicated — do not co-prescribe
Insulin / sulfonylurea High Consider dose adjustments; increase SMBG frequency
Strong CYP3A4/CYP2C8 inhibitors Moderate to high Review interaction specifics; consider alternative or monitoring

Legal status and availability in the UK

Because repaglinide is prescription-only, it cannot be bought over the counter in the UK.

In our online pharmacy, NovoNorm is available without a prescription, with discreet delivery to the United Kingdom in 9–21 days.

Mechanism and pharmacology

Simplified explanation

Repaglinide is a meglitinide, or glinide, which acts as a rapid-acting insulin secretagogue.

It stimulates pancreatic beta cells to release insulin around mealtimes, reducing postprandial glucose peaks.

Because of rapid onset and short duration of action, it is taken immediately before meals for targeted control of prandial glucose.

Clinical terms

Drug class
Meglitinide (glinide) — rapid-acting prandial insulin secretagogue.
Pharmacokinetics
Rapid absorption with quick onset and short half-life, making it suitable for mealtime dosing and patients who need targeted prandial control.
Clinical implication
Useful for patients with predominant postprandial hyperglycaemia or irregular meal schedules when careful counselling can be provided.

Indications and off-label uses

MHRA-approved uses

Repaglinide is authorised for the treatment of type 2 diabetes mellitus as an adjunct to diet and exercise in adults to control postprandial glucose.

It is not indicated for type 1 diabetes or for diabetic ketoacidosis.

Off-label practices in NHS and private care

  • Clinicians may select repaglinide for patients intolerant of metformin or where metformin is contraindicated.
  • It may be chosen for patients with predominant postprandial hyperglycaemia or those who need dosing flexibility around meals.
  • In elderly patients, off-label use must be individualised and documented with clear justification and informed consent.

Clinician decision checklist:

  • Document reason for off-label use and expected benefit.
  • Review renal and hepatic function before starting.
  • Provide written hypoglycaemia and sick-day guidance.

Alternatives matrix

NHS prescribing alternatives (comparison table)

Drug class Mechanism Typical advantage Main risk
Metformin Biguanide — reduces hepatic glucose output First-line, weight neutral, cardiovascular benefits GI upset, not suitable in severe renal impairment
Sulfonylureas (Glimepiride) Stimulate insulin release (longer acting) Effective and well established Higher risk of prolonged hypoglycaemia
Nateglinide (other meglitinide) Rapid-acting insulin secretagogue Similar prandial control with dosing flexibility Hypoglycaemia risk
DPP-4 inhibitors (sitagliptin) Incretin enhancer Low hypoglycaemia risk, well tolerated Modest efficacy on HbA1c
SGLT2 inhibitors (empagliflozin) Inhibit renal glucose reabsorption Weight loss, CV and renal benefits in some patients Genital infections, volume depletion

Pros and cons checklist

  • Pros: Targeted prandial control, rapid onset, flexible dosing around meals.
  • Cons: Hypoglycaemia risk, less effective for fasting hyperglycaemia, contraindicated in severe liver disease and with gemfibrozil.

Common questions

  • Can I drink alcohol while taking repaglinide?

    Alcohol increases the risk of hypoglycaemia and can blunt warning symptoms.

    Avoid binge drinking and discuss usual alcohol intake with your clinician.

  • Can repaglinide be used with metformin?

    Yes; combination therapy with metformin is common when metformin alone is insufficient and tolerated.

    Monitor for hypoglycaemia and review renal and hepatic function.

  • Is repaglinide safe in pregnancy?

    Repaglinide is not routinely recommended in pregnancy and specialist advice is required.

    Insulin is usually preferred for glucose control in pregnancy; discuss with your obstetric diabetes team.

For NHS pregnancy and diabetes guidance see NHS.uk diabetes in pregnancy pages.

Registration and regulation

MHRA approval process

Repaglinide formulations such as NovoNorm are authorised by the MHRA for type 2 diabetes.

Prescribers and dispensers should ensure products dispensed are authorised and include the patient information leaflet.

Report suspected adverse reactions via the MHRA Yellow Card scheme.

NHS prescribing framework

Prescribing should follow local NHS formularies and any shared care guidelines in place.

The Electronic Prescription Service streamlines prescription delivery but does not change pharmacist counselling responsibilities.

For private prescriptions, document brand/generic choices and patient counselling in the record.

  • Licence check for the product being dispensed.
  • Confirm contraindications and interacting drugs.
  • Advise on Yellow Card reporting for adverse events.

Storage and handling

UK household storage (cold/damp climate)

Store repaglinide at room temperature.

Protect tablets from moisture and heat, and keep in the original packaging until use.

In UK homes avoid storing medicines in humid or hot places such as bathrooms or near kitchen sinks and radiators.

Guidance from NHS and pharmacists

Advise patients on transporting medicines during travel and on differences between blister packs and bottles.

Unused or expired repaglinide should be returned to a pharmacy for safe disposal and not thrown in household waste or flushed down the toilet.

Recommended temperature range
Room temperature, in a dry place.
Handling
Keep in original pack until needed to protect from moisture.

Guidelines for proper use

UK pharmacist counselling style

Counsel on timing: take repaglinide 0–30 minutes before meals to reduce post-meal glucose spikes.

Explain signs of hypoglycaemia and immediate treatment with fast-acting carbohydrate (e.g., glucose tablets or sugary drink).

Confirm missed-dose rules: if the meal is skipped, skip the dose and do not double up.

Highlight important interactions — specifically gemfibrozil is contraindicated — and document counselling.

Encourage patients to use glucose ID and to have a hypoglycaemia emergency plan.

NHS patient safety advice

Monitor HbA1c and review renal and hepatic function periodically while on repaglinide.

Provide written sick-day rules, including when to stop certain glucose-lowering medicines during vomiting or diarrhoea.

Record and review any hypoglycaemia episodes and reassess driving and occupational fitness if needed.

  • Symptoms of hypoglycaemia: sweating, tremor, confusion, hunger, palpitations.
  • Immediate actions: take 15–20 g of rapid-acting carbohydrate; re-check glucose after 10–15 minutes and repeat if low.
  • When to call 999: if severe confusion, seizures, loss of consciousness or inability to swallow.

Delivery across the United Kingdom

City Region Delivery Time
London England 9–21 days
Birmingham England 9–21 days
Manchester England 9–21 days
Glasgow Scotland 9–21 days
Leeds England 9–21 days
Liverpool England 9–21 days
Bristol England 9–21 days
Sheffield England 9–21 days
Newcastle Upon Tyne England 9–21 days
Nottingham England 9–21 days
Leicester England 9–21 days
Cardiff Wales 9–21 days
Belfast Northern Ireland 9–21 days

Final notes

Repaglinide (NovoNorm and generics) is a targeted prandial glucose regulator effective for post-meal control in adults with type 2 diabetes.

Choice of therapy should balance glycaemic benefit against hypoglycaemia risk, especially in elderly patients and those with hepatic or renal impairment.

Always follow MHRA, BNF and local formulary guidance when prescribing or dispensing repaglinide and report suspected safety issues via Yellow Card.

For personalised advice, consult your GP, diabetes specialist or pharmacist and ensure you have an up-to-date hypoglycaemia action plan.

Related products